✨ Free AI Report
Innovent Biologics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Innovent Biologics, Inc.
Research Preview

Innovent Biologics, Inc.: Business Overview, Financials & Competitive Analysis

Innovent Biologics is a biopharmaceutical company principally engaged in research, development, production and sales of innovative medicines for cancer, cardiovascular and metabolic, autoimmune and eye diseases. As on...

Analyst-debate audio for Innovent Biologics, Inc.

AskCyborg analysts argue the bull and bear cases for Innovent Biologics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Innovent Biologics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Leading Chinese biotech with diversified oncology/immunology pipeline, bolstered by strategic partnerships and accelerating...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Oncology and Immunology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Innovent Biologics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Innovent Biologics, Inc. Overview

Pro stress-test →

Innovent Biologics is a biopharmaceutical company principally engaged in research, development, production and sales of innovative medicines for cancer, cardiovascular and metabolic, autoimmune and eye diseases. As one of the leading biotechnology companies in China listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025.

Strategic Profile

Pro stress-test →

Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Competitive Landscape

Pro stress-test →

Innovent Biologics is one of the leading biotechnology companies in China. The company competes with both domestic Chinese biotech firms and global pharmaceutical companies in oncology, immunology, and metabolic disease spaces. Key differentiators include its established commercial portfolio, regulatory approvals on reimbursement lists, and major global partnerships.

Industry Context

Innovent Biologics, Inc. operates in Biopharmaceuticals / Oncology and Immunology.

Key facts

Founded: 2011 · Headquarters: Suzhou, China · Employees: 6,190 · Revenue: RMB 10B+ · Market cap: $146.1B HKD

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Innovent Biologics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Innovent Biologics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

WuXi BiologicsLeading Chinese biotech and CDMO services provider→Roche/Genentech OncologyGlobal oncology and immunology leader→Eli Lilly OncologyGlobal pharma with oncology and metabolic disease focus→BeiGeneChinese biotech with oncology focus→

Compare Innovent Biologics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Innovent Biologics, Inc. operates in Biopharmaceuticals / Oncology and Immunology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Oncology and Immunology research →
NEW · MCP server

Ask your AI assistant about Innovent Biologics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Innovent Biologics, Inc. and its top competitor on Cyborg Score”
“What did Innovent Biologics, Inc. do this quarter?”
“Is Innovent Biologics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Innovent Biologics, Inc. do?+
Innovent Biologics is a biopharmaceutical company principally engaged in research, development, production and sales of innovative medicines for cancer, cardiovascular and metabolic, autoimmune and eye diseases. As on...
What is Innovent Biologics, Inc.'s Cyborg Score?+
Innovent Biologics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Innovent Biologics, Inc.'s main competitors?+
Named competitors include WuXi Biologics, Roche/Genentech Oncology, Eli Lilly Oncology, BeiGene. The full competitive landscape is in the AskCyborg report.
How can I get the full Innovent Biologics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Innovent Biologics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Innovent Biologics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Jazz Pharmaceuticals plc7WuXi BiologicsTop companies in Biopharmaceuticals by Cyborg Score